What is more intriguing is that PD-L1 or PD-1 inhibitors in combination with chemotherapy seem to be more successful (PFS of 0.63; 95% CI, 0.42-0.94) in NSCLC patients who had an EGFR mutation. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.